`
`Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-Cell Lymphoma
`
`Latest version (submitted May 5, 2016) on ClinicalTrials.gov
`
`A study version is represented by a row in the table.
`
`Select two study versions to compare. One each from columns A and B.
`
`Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only
`applies to the Protocol section of the study.
`
`Click "Compare" to do the comparison and show the differences.
`
`Select a version's Submitted Date link to see a rendering of the study for that version.
`
`The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
`
`Hover over the "Recruitment Status" to see how the study's recruitment status changed.
`
`Study edits or deletions are displayed in red .
`
`Study additions are displayed in green .
`
`Study Record Versions
`
`Version
`
`A
`
`B
`
`Submitted Date
`
`Changes
`
`1
`
`2
`
`3
`
`March 21, 2008 None (earliest Version on record)
`
`April 25, 2008 Study Status
`
`June 2, 2008 Study Status
`
`Exhibit 2079
`Page 01 of 08
`
`
`
`Version
`
`A
`
`B
`
`Submitted Date
`
`Changes
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`September 19, 2008 Study Status, Outcome Measures and Study Identification
`
`March 3, 2009 Study Status
`
`March 10, 2009 Recruitment Status, Contacts/Locations and Study Status
`
`August 30, 2011 Sponsor/Collaborators, Study Status, Study Identification and References
`
`January 3, 2012 Recruitment Status, Study Status and Study Design
`
`May 5, 2016 Arms and Interventions, Study Status, Study Design and Study Identification
`
`Compare
`
` Comparison Format:
`
` Merged
` Side-by-Side
`
`Scroll up to access the controls
`
`Study NCT00644124
`Submitted Date: March 21, 2008 (v1)
`
` Study Identification
`
`Unique Protocol ID: TCD10173
`
`Brief Title: Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-Cell Lymphoma
`
`Official Title: A Phase I Open-Label Dose-Escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in
`Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non
`Hodgkin's B-Cell Lymphoma
`
`Secondary IDs: AVE0005
`EudraCT 2007-003737-16
`
`Exhibit 2079
`Page 02 of 08
`
`
`
` Study Status
`
`Record Verification: March 2008
`
`Overall Status: Recruiting
`
`Study Start: March 2008
`
`Primary Completion:
`
`Study Completion:
`
`First Submitted: March 21, 2008
`
`First Submitted that
`Met QC Criteria:
`
`March 21, 2008
`
`First Posted: March 26, 2008 [Estimate]
`
`Last Update Submitted that
`Met QC Criteria:
`
`March 21, 2008
`
`Last Update Posted: March 26, 2008 [Estimate]
`
` Sponsor/Collaborators
`
`Sponsor: Sanofi
`
`Responsible Party:
`
`Collaborators: Regeneron Pharmaceuticals
`
`Exhibit 2079
`Page 03 of 08
`
`
`
` Oversight
`
`U.S. FDA-regulated Drug:
`
`U.S. FDA-regulated Device:
`
`Data Monitoring: No
`
` Study Description
`
`Brief Summary: The purpose of this study is to determine the selected dose of aflibercept when it is combined with R-
`CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal
`Methotrexate) administered every 2 weeks or every 3 weeks, in non Hodgkin B-cell lymphoma, and to
`determine how the body handles aflibercept when it is administered with R-CHOP.
`
`Detailed Description:
`
` Conditions
`
`Conditions: Lymphoma, Non-Hodgkin
`
`Keywords: Non-Hodgkin's lymphoma
`angiogenesis inhibitors
`CHOP protocol
`
`Exhibit 2079
`Page 04 of 08
`
`
`
` Study Design
`
`Study Type: Interventional
`
`Primary Purpose: Treatment
`
`Study Phase: Phase 1
`
`Interventional Study Model: Parallel Assignment
`
`Number of Arms:
`
`Masking: None (Open Label)
`
`Allocation: Non-Randomized
`
`Enrollment: 50 [Anticipated]
`
` Arms and Interventions
`
`Intervention Details:
`
`Drug: aflibercept
`in combination with standard treatment R-CHOP
`
`Exhibit 2079
`Page 05 of 08
`
`
`
` Outcome Measures
`
`Primary Outcome Measures:
`
`1. selected dose of aflibercept based on Dose Limiting Toxicities observed
`[ Time Frame: cycle 1 +/- 2 ]
`
`
`Secondary Outcome Measures:
`
`1. Adverse events
`[ Time Frame: treatment period ]
`
`
`2. Response rate
`[ Time Frame: cycle 2, 4 and 8 ]
`
`
`3. Progression free survival
`
`4. Biomarkers
`
` Eligibility
`
`Minimum Age: 18 Years
`
`Maximum Age:
`
`Sex: All
`
`Gender Based:
`
`Accepts Healthy Volunteers: No
`
`Exhibit 2079
`Page 06 of 08
`
`
`
`Criteria: Inclusion Criteria:
`
`Patients with non-Hodgkin B-cell lymphoma, good condition, not previously treated
`
`Exclusion Criteria:
`
`Contraindication to any drug contained in the R-CHOP
`(Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate)
`Less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of
`inclusion
`Cerebral or leptomeningeal involvement.
`History of another neoplasm (Adequately treated basal cell or squamous cell skin cancers,
`carcinoma in situ of the cervix, or any other cancer from which the patient has been disease free for
`> 5 years are allowed)
`Participation in another clinical trial and any concurrent treatment with any investigational drug within
`30 days prior to the first drug intake
`Any acute or chronic medical condition, which could impair the ability of the patient to participate to
`the study or could interfere with interpretation of study results
`Uncontrolled diabetes mellitus
`Uncontrolled hypertension
`Abnormal kidney function
`Evidence of clinically significant bleeding diathesis, non-healing wound or underlying coagulopathy
`Pregnant or breast-feeding woman, or patient with reproductive potential (male, female) without an
`effective method of contraception
`History of hypersensitivity to any Trap agents or recombinant proteins
`
`Exhibit 2079
`Page 07 of 08
`
`
`
` Contacts/Locations
`
`Central Contact Person: Public Registry ICD
`Email: GV-Contact-us@sanofi-aventis.com
`Study Officials: Corinne Haioun, MD
`Principal Investigator
`Groupe d'Etudes du Lymphome de l'Adulte
`Locations: France
`Sanofi-Aventis Administrative Office
`[Recruiting]
`Paris, France
`Contact:
`
`Contact: GV-Contact-us@sanofi-aventis.com
`
` IPDSharing
`
`Plan to Share IPD:
`
` References
`
`Citations:
`
`Links: URL: http://www.sanofi-aventis.com
`Description: Related Info
`
`
`
`Available IPD/Information:
`
`Scroll up to access the controls
`
`Scroll to the Study top
`
`U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services
`
`Exhibit 2079
`Page 08 of 08
`
`